Sagimet Biosciences announced pricing of a public offering of $112.5 M Series A common stock. Read more: https://lnkd.in/gJt5NUPy
Sagimet Biosciences’ Post
More Relevant Posts
-
Biohaven's stock fell 16% due to delayed updates on its key drug, BHV-1300, unsettling investors despite some positive results. This situation highlights the critical impact of transparency in biotech communications. Key questions - ▪️ How do disclosure delays affect investor trust and stock prices? ▪️ Could clearer communication have softened the blow to Biohaven's stock? #Biotech #InvestorRelations #Biohaven
To view or add a comment, sign in
-
President & CEO of Cytonics | Innovating Regenerative Medicine | Biotech Investor | Johns Hopkins School of Medicine | Moving From Insurmountable Challenge To Almost Certain Failure With Unbridled Enthusiasm
The #biotech sector is riding a wave of resurgence, with the SPDR S&P Biotech ETF ($XBI) breaking past the $100 mark, fueled by #investor optimism and groundbreaking developments like Viking Therapeutics' promising #obesity drug. This upswing is further bolstered by anticipation of interest rate cuts and a surge in M&A activity, despite lingering concerns over the timing of these cuts. The industry's total enterprise value has soared by 21.5% this year, with the biotech market up 66% from its October low. Stifel's Tim Opler suggests that the XBI could climb even higher, potentially reaching 120 or above. This resurgence marks a pivotal moment for biotech, heralding a new era of innovation and investment opportunities that could revolutionize #healthcare. #biotechnology #stockmarket #investing #venturecapital https://lnkd.in/eVyZAWzg
Biotech index rises above $100 mark for first time in two years
https://endpts.com
To view or add a comment, sign in
-
Head of Life Science Division @ Kinetica | North America, Europe & APAC Recruitment Solutions | 12,000+ Followers
Olink Proteomics Shares Take a Hit as German Regulators Intensify Scrutiny of Pending Acquisition by Thermo Fisher. the proteomics firm, saw a significant decline of over 8 percent in its shares during Tuesday's afternoon trading on the Nasdaq. This drop came after the company revealed that German regulators are delving deeper into its proposed $3.1 billion acquisition by Thermo Fisher Scientific. In a disclosure to the US Securities and Exchange Commission on Tuesday, Olink stated that the German Bundeskartellamt, the country's competition regulatory body, has informed Thermo Fisher of its initiation of a Phase 2 review regarding the pending acquisition. What might be the potential implications of the German Bundeskartellamt's Phase 2 review on Olink's acquisition by Thermo Fisher Scientific? #proteomics #acquistion #phase2 #olink #thermo
To view or add a comment, sign in
-
CIO Copernicus Wealth Management | Thought Leader bridging Investment Strategy and Al | Public speaker on Global Macroeconomics, Market Strategy, Digital Finance & Innovation
𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 𝟐𝟎𝟐𝟒 𝐕𝐢𝐝𝐞𝐨 𝐒𝐞𝐫𝐢𝐞𝐬 - 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬! My three ideas: 1️⃣ Gold - real assets over nominal assets! 2️⃣ Pharma and Biotech - growth outlook intact & attractive valuation! 3️⃣ S&P 493 - stock picking remains key! . . . and yes - I still like Tech but very selectively! What are your investment ideas for 2024? Would love to hear yours, please comment in the section below. 👇 #gold #pharma #biotech #usequities #thomaswille
To view or add a comment, sign in
-
NightHawk Biosciences, Inc is changing its business focus to concentrate solely on biomanufacturing, specifically through its Scorpius BioManufacturing, Inc. subsidiary. This is a testament to the business, showing the market potential moving forward. It will be exciting to see how things progress in 2024 and if other similar businesses will do the same! #CDMO #BioManufacturing #ScorpiusBio #MasonHaring #CommercialAwareness 🧬 Is this a smart move by NightHawk, what are your thoughts? https://lnkd.in/e2VYVVRd
NightHawk Biosciences Unveils Pure-Play Biomanufacturing CDMO
contractpharma.com
To view or add a comment, sign in
-
Thanks to Jill Malandrino for discussing our latest perspectives on Nasdaq TradeTalks about the capital utilization efficiency of life science companies. The take-home message is two-fold: Those life sciences companies that adapted an active portfolio management strategy returned 67% more capital to their shareholders when compared to those that did not engage in any buy or sell activity. We also discussed the M&A outlook for 2024. After the "mad dash" in December, which kicked off a strong new calendar year, we are increasingly optimistic about a more favorable #macroeconomic environment. You can watch the interview here: https://lnkd.in/dJpCR3cd. #MedTech #BioTech #pharma #mergersandacquisitions
To view or add a comment, sign in
-
SFBN Feed: It takes GUTS to be BOLD: A look at the new biotech tickers https://lnkd.in/gAijC39m As the public markets heat up in biotech, industry insiders expect a small drumbeat of IPOs later this spring, and that means a new set of stock tickers to track. Next up is BOLD, the [...] #BayArea #SanFrancisco #Biotech #Lifescience #News
It takes GUTS to be BOLD: A look at the new biotech tickers
https://sfbn.org
To view or add a comment, sign in
-
Thermo Fisher has agreed to acquire Olink Holding for approximately $3.1 billion, with the aim of enhancing its footprint in the field of proteomics. The transaction is set to be finalized in mid-2024 and will be financed through a combination of cash and debt. Under Thermo Fisher's stewardship, Olink foresees a promising revenue projection of over $200 million for the year 2024, with a robust mid-teen’s growth trajectory. Click here to read more: https://lnkd.in/gegqFKzq Comment your thoughts and opinions down below! #thermofisher #acquisition #Olink #venturecapital #privateequity #deerbornedifference
Thermo Fisher Scientific to buy Olink in $3.1 billion deal
reuters.com
To view or add a comment, sign in
2,946 followers